Hematopoietic stem cell transplant complications
Late complications of hematopoietic stem cell transplantation (HSCT) arise beyond day 100, when impaired cellular and humoral immunity and chronic graft-versus-host disease drive infection with encapsulated bacteria, cytomegalovirus, varicella-zoster virus, Pneumocystis, and molds, alongside posttransplant lymphoproliferative disorder, delayed pulmonary toxicity, thrombotic microangiopathy, secondary cancer, and infertility. Care rests on early evaluation of any fever, pathogen-specific treatment, prophylaxis, irradiated blood products, and a full revaccination series.
- Topic reviewThe full article, organized the way the exam asks it.
- ABIM-format MCQsVignettes with an explanation for every wrong answer.
- Key factsThe numbers and thresholds worth memorizing, up front.
- AI tutorMedBrain answers the question you're stuck on.
What this article covers
- Overview
Definition: late HSCT complications are the infectious and noninfectious problems that arise in the late phase, more than 100 days after transplant, in survivors who remain free of relapse.
- Epidemiology
Indications define the population: autologous HSCT for multiple myeloma and relapsed aggressive lymphoma; allogeneic HSCT for high-risk acute leukemia, myelodysplastic syndrome, aplastic anemia, and selected hemoglobinopathies.
- Risk factors
Chronic GVHD and its treatment: the strongest driver of late infection, through immune dysregulation, mucosal barrier breakdown, and the immunosuppressive drugs used to control it, which also raise invasive fungal risk.
- Pathophysiology
Three immune phases: preengraftment (under 30 days, neutropenia and mucositis), postengraftment (30 to 100 days, impaired cellular immunity and acute GVHD), and late (over 100 days, impaired cellular and humoral immunity and chronic GVHD).
- Clinical features
Fever: the most urgent presentation, from encapsulated bacteria, CMV, molds, or Pneumocystis.
- Differential diagnosis
Relapse of the original malignancy: recurrent cytopenias, circulating blasts, or new masses; distinguished by marrow or tissue biopsy and the leading cause of late death.
- Diagnosis
How the diagnosis is established: a late complication is defined by timing (onset more than 100 days after transplant) and confirmed by the gold standard for the specific complication: CMV organ…
- Management
First, evaluate any fever early for infection, obtaining cultures and CMV NAAT before targeting treatment to the pathogen found.
- Complications
Death from infection: CMV pneumonia, invasive molds, and pneumococcal sepsis.
- Prognosis
Favorable candidates do well: survival of young, good-risk patients after HSCT for aplastic anemia exceeds 80%.
- Prevention
Prevent Pneumocystis with trimethoprim-sulfamethoxazole double-strength (160 mg/800 mg) PO once daily, or single-strength once daily, continued throughout the immunosuppression that confers risk; it…
Read the whole article
Subscribing to Internal Medicine opens every article, the full question bank and MedBrain, on the web, iPhone and Android.
Related articles
- Graft-versus-host disease
Graft-versus-host disease is a complication of allogeneic hematopoietic stem cell transplantation in which donor T cells attack recipient tissues, classically the skin, liver, and gut in the acute form and multi-organ fibrosis in the chronic form. Diagnosis is clinical, supported by biopsy, and management is prophylaxis with a calcineurin inhibitor plus methotrexate and treatment with corticosteroids, escalating to agents such as ruxolitinib for steroid-refractory disease.
- Solid organ transplant complications
Solid organ transplant complications arise from the immunosuppression that prevents graft rejection, producing a predictable, time-dependent pattern of rejection, opportunistic infection, and malignancy. Diagnosis rests on allograft biopsy and pathogen-specific testing, and first-line treatment pairs targeted therapy of the complication with a deliberate adjustment, not blanket discontinuation, of the immunosuppressive regimen.
- Cytomegalovirus (CMV) infection
Cytomegalovirus is a ubiquitous herpesvirus that is usually asymptomatic or causes a heterophile-negative mononucleosis-like illness in healthy hosts, but reactivates to cause retinitis, colitis, pneumonitis, or encephalitis in transplant recipients and patients with AIDS; treatment is systemic ganciclovir or valganciclovir, with foscarnet and cidofovir reserved for resistance or intolerance.
- Pneumocystis jirovecii pneumonia
Pneumocystis jirovecii pneumonia is a subacute, often hypoxic pneumonia in patients with CD4 counts below 200/mcL or comparable immunosuppression, diagnosed by organism visualization on induced sputum or bronchoalveolar lavage and treated with 21 days of high-dose trimethoprim-sulfamethoxazole plus adjunctive steroids when hypoxic.
- Aspergillosis
Invasive aspergillosis is an angioinvasive mold infection of neutropenic and immunosuppressed hosts that begins in the respiratory tract and disseminates hematogenously, diagnosed with CT, galactomannan, and biopsy, and treated first-line with voriconazole.
- Herpes zoster (shingles)
Herpes zoster is reactivation of latent varicella-zoster virus from a sensory ganglion, producing a painful, dermatomal vesicular rash that does not cross the midline, most common in adults older than 60 years and in immunosuppressed hosts; diagnosis is clinical, confirmed by VZV PCR when needed, and antiviral therapy started within 72 hours of rash onset shortens the illness and reduces postherpetic neuralgia.
- Vaccines
Vaccines are live attenuated, inactivated, subunit, conjugate, or toxoid preparations that induce antigen-specific active immunity to prevent infection or its complications before exposure occurs. Selection follows the age- and risk-based Advisory Committee on Immunization Practices schedule, with routine adult boosting such as Tdap every 10 years, and inactivated regimens substituted whenever a live vaccine is contraindicated by pregnancy or immunosuppression.
- Thrombotic thrombocytopenic purpura (TTP)
Thrombotic thrombocytopenic purpura is a thrombotic microangiopathy caused by severe ADAMTS13 deficiency that lets ultralarge von Willebrand factor multimers drive platelet microthrombi; the key dyad of microangiopathic hemolytic anemia plus thrombocytopenia without another cause mandates the PLASMIC score, an ADAMTS13 activity and inhibitor level, and emergent plasma exchange started before results return.